Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03511534 · ClinicalTrials.gov registry record · NA
Open/Aftercare Treatment for Participants Diagnosed With Obsessive Compulsive Disorder
A NA study of OCD, sponsored by Stanford University.
- Active
- Registry status
- NA
- Development phase
- 200
- Enrollment target
- 1
- Study location
NCT03511534: Active NA study of OCD, sponsored by Stanford University.
NCT03511534 is a NA study of OCD that is active but no longer recruiting, run by Stanford University. The registered enrollment target is 200 participants, below the 807-participant average among 18 other OCD trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03511534, a NA study of OCD, is active but no longer recruiting, sponsored by Stanford University.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to provide participants diagnosed with obsessive compulsive disorder (OCD) and completed one of the active study protocols at the Rodriguez Lab, with open/aftercare treatment.
Primary Outcome
Improvement in OCD severity is measured by the YBOCS (Yale Brown Obsessive-Compulsive Scale), a gold standard measure of obsessions and compulsions. For the YBOCS the minimum units are 0 and Maximum units on the total scale are 40. The higher the number on the YBOCS, the more severe the symptoms. Response is defined as at least a 35% reduction on the YBOCS.
Conditions Studied
Interventions
- BEHAVIORAL Psychotherapy
- OTHER Pharmacotherapy
Study Locations (1)
California
- Stanford University - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2017-06-23 |
| Est. Completion | 2026-06 |
| Phase | NA |
What the registry record for NCT03511534 still lists
NCT03511534 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 807-participant average among 18 other OCD trials with a reported enrollment target (75% lower).
The record links to 1 condition, with OCD appearing as the primary indexed condition, and to 2 interventions - of which Psychotherapy is the first listed.
NCT03511534 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT03511534 about?
NCT03511534 is a clinical study titled "Open/Aftercare Treatment for Participants Diagnosed With Obsessive Compulsive Disorder". The purpose of this study is to provide participants diagnosed with obsessive compulsive disorder (OCD) and completed one of the active study protocols at the Rodriguez Lab, with open/aftercare treatment.
What is the current status of trial NCT03511534?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 200 participants. The study started on 2017-06-23. Estimated completion is 2026-06.
What conditions does trial NCT03511534 study?
This clinical trial studies the following conditions: OCD.
What interventions are being tested in trial NCT03511534?
The interventions under investigation include: Psychotherapy (BEHAVIORAL), Pharmacotherapy (OTHER).
Who is sponsoring clinical trial NCT03511534?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03511534 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for OCD
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03511534's enrollment target sits among peer trials
200 6th of 18 higher than 12 of 18 other OCD trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other OCD trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Neuromodulation for a Novel OCD Biomarker and Treatment
RECRUITING · NA
-
Personalized DBS for OCD Guided by Stereoencephalography Mapping
RECRUITING · NA
-
Neurostimulation Versus Therapy for Problems With Emotions
RECRUITING · NA
-
How Hormones and Exposure and Response Prevention (EX/RP) Affect the Brain of People With OCD
RECRUITING · NA
-
Implementing Team-Based Treatment for Pediatric Anxiety in Community Mental Health Settings
RECRUITING · NA
-
Multi-session, Personalized Cognitive Bias Modification for Thought-Action-Fusion
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI